Reconsidering FDA Guidelines: A Single-Center Experience of Prolonged Impella 5.5 Support
Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery · 2024-01 · 19 (1) · 46-53
DOI: 10.1177/15569845231212157 ↗Kurz gefasst
Leitlinie in der Zeitschrift Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, online erschienen am 27.11.2023. Verfasst von Carlos Alberto Valdes und 13 weiteren Autor:innen. Beteiligte Einrichtung: University of Florida, Gainesville, FL, USA. Hauptthemen laut MEDLINE: Heart Transplantation, Heart-Assist Devices. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Objective
Impella 5.5 (Abiomed, Danvers, MA, USA) is approved by the US Food and Drug Administration (FDA) for mechanical circulatory support for ≤14 days. It is unknown whether prolonged support is associated with worse outcomes. We sought to review our single-center experience with Impella 5.5 and compare outcomes based on support duration.
Methods
We retrospectively reviewed adult patients (≥18 years old) supported with Impella 5.5 at our institution (May 2020 to April 2023). Patients on prolonged support (>14 days) were compared with those supported for ≤14 days.
Results
There were 31 patients supported with Impella 5.5 including 14 (45.2%) supported >14 days. Median support duration for those on prolonged support was 43.5 (interquartile range [IQR] 25 to 63.5) days versus 8 (IQR 6, 13) days for those who were not ( P < 0.001). Overall, the device-related complication rate was 9.7% and did not differ between groups ( P = 0.08). Overall, 30-day postimplant survival was 71% and did not differ by support duration ( P = 0.2). In-hospital mortality was 32% and did not differ between cohorts ( P > 0.99). Among those surviving to explant ( n = 22), long-term strategy included bridge to durable ventricular assist device (18%, n = 4), cardiac transplant (55%, n = 12), and cardiac recovery (27%, n = 6).
Conclusions
High-risk patients with cardiogenic shock may be supported with Impella 5.5 beyond the FDA-approved duration without increased risk of complications or mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Florida, Gainesville, FL, USA.
ORCID-Profile: Carlos Alberto Valdes, Griffin Stinson, Ahmet Bilgili
Zitieren
APA
Valdes, C. A., Stinson, G., Sharaf, O. M., Jimenez Contreras, F., Bilgili, A., Ahmed, M. M., Vilaro, J., Parker, A. M., Al-Ani, M. A. Z., Demos, D., Aranda, J., Bleiweis, M., Beaver, T. M., & Jeng, E. I. (2024). Reconsidering FDA Guidelines: A Single-Center Experience of Prolonged Impella 5.5 Support. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 19(1), 46-53. https://doi.org/10.1177/15569845231212157
Vancouver
Valdes CA, Stinson G, Sharaf OM, Jimenez Contreras F, Bilgili A, Ahmed MM, et al. Reconsidering FDA Guidelines: A Single-Center Experience of Prolonged Impella 5.5 Support. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery. 2024;19(1):46-53. doi:10.1177/15569845231212157
BibTeX
@article{Valdes2024,
author = {Valdes, Carlos Alberto and Stinson, Griffin and Sharaf, Omar M and Jimenez Contreras, Fabian and Bilgili, Ahmet and Ahmed, Mustafa M and Vilaro, Juan and Parker, Alex M and Al-Ani, Mohammad A Z and Demos, Daniel and Aranda, Juan and Bleiweis, Mark and Beaver, Thomas M and Jeng, Eric I},
title = {Reconsidering FDA Guidelines: A Single-Center Experience of Prolonged Impella 5.5 Support},
journal = {Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery},
year = {2024},
volume = {19},
number = {1},
pages = {46--53},
doi = {10.1177/15569845231212157}
}
EUVIMED